April D Thames1, Taylor P Kuhn2, Timothy J Williamson3, Jacob D Jones2, Zanjbeel Mahmood2, Andrea Hammond4. 1. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 740 Westwood Plaza 28-263, Los Angeles, CA 90095, USA. Electronic address: athames@mednet.ucla.edu. 2. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 740 Westwood Plaza 28-263, Los Angeles, CA 90095, USA. 3. Department of Psychology, University of California Los Angeles, Franz Hall, 502 Portola Plaza, Los Angeles, CA 90095, USA. 4. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 740 Westwood Plaza 28-263, Los Angeles, CA 90095, USA; Department of Psychology, California State University, Northridge, 18111 Nordhoff Street, Northridge, CA 91330, USA.
Abstract
BACKGROUND: The current study examined the independent and interactive effects of HIV and marijuana (MJ) use on brain structure and cognitive function among a sample of HIV-positive (HIV+) and HIV-negative (HIV-) individuals. METHODS: Participants (HIV+, n=48; HIV-, n=29) individuals underwent cognitive testing, questionnaires about substance use, and brain MRI. The HIV+ group was clinically stable based upon current plasma CD4 count, 50% had undetectable viral load (i.e.,<20 copies/mL), and all were on a stable regimen of cART. RESULTS: For HIV+ and HIV- participants, higher levels of MJ use were associated with smaller volumes in the entorhinal cortex and fusiform gyrus. HIV status (but not MJ use) was associated with cingulate thickness, such that HIV+ participants evidenced smaller thickness of the cingulate, as compared to HIV- controls. Regarding neurocognitive functioning, there was a HIV*MJ interactive effect on global cognition, such that when the amount of MJ use was less than 1.43g per week, the HIV- group displayed significantly better neurocognitive performance than the HIV+ group (t=3.14, p=0.002). However, when MJ use reached 1.43g per week, there were no significant HIV group differences in global cognitive performance (t=1.39, p=0.168). CONCLUSIONS: Our results show independent and interactive effects of HIV and MJ on brain structure and cognition. However, our results do not support that HIV+ MJ users are at greater risk for adverse brain or cognitive outcomes compared to HIV- MJ users.
BACKGROUND: The current study examined the independent and interactive effects of HIV and marijuana (MJ) use on brain structure and cognitive function among a sample of HIV-positive (HIV+) and HIV-negative (HIV-) individuals. METHODS:Participants (HIV+, n=48; HIV-, n=29) individuals underwent cognitive testing, questionnaires about substance use, and brain MRI. The HIV+ group was clinically stable based upon current plasma CD4 count, 50% had undetectable viral load (i.e.,<20 copies/mL), and all were on a stable regimen of cART. RESULTS: For HIV+ and HIV- participants, higher levels of MJ use were associated with smaller volumes in the entorhinal cortex and fusiform gyrus. HIV status (but not MJ use) was associated with cingulate thickness, such that HIV+ participants evidenced smaller thickness of the cingulate, as compared to HIV- controls. Regarding neurocognitive functioning, there was a HIV*MJ interactive effect on global cognition, such that when the amount of MJ use was less than 1.43g per week, the HIV- group displayed significantly better neurocognitive performance than the HIV+ group (t=3.14, p=0.002). However, when MJ use reached 1.43g per week, there were no significant HIV group differences in global cognitive performance (t=1.39, p=0.168). CONCLUSIONS: Our results show independent and interactive effects of HIV and MJ on brain structure and cognition. However, our results do not support that HIV+ MJ users are at greater risk for adverse brain or cognitive outcomes compared to HIV- MJ users.
Authors: Francesca M Filbey; Sina Aslan; Vince D Calhoun; Jeffrey S Spence; Eswar Damaraju; Arvind Caprihan; Judith Segall Journal: Proc Natl Acad Sci U S A Date: 2014-11-10 Impact factor: 11.205
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray Journal: Psychol Med Date: 2009-04-01 Impact factor: 7.723
Authors: Joanna Jacobus; Lindsay M Squeglia; Alejandro D Meruelo; Norma Castro; Ty Brumback; Jay N Giedd; Susan F Tapert Journal: Dev Cogn Neurosci Date: 2015-04-27 Impact factor: 6.464
Authors: Laura Koenders; Janna Cousijn; Wilhelmina A M Vingerhoets; Wim van den Brink; Reinout W Wiers; Carin J Meijer; Marise W J Machielsen; Dick J Veltman; Anneke E Goudriaan; Lieuwe de Haan Journal: PLoS One Date: 2016-05-25 Impact factor: 3.240
Authors: Christina S Meade; Andrea L Hobkirk; Sheri L Towe; Nan-Kuei Chen; Ryan P Bell; Scott A Huettel Journal: Drug Alcohol Depend Date: 2017-07-08 Impact factor: 4.492
Authors: Rowan Saloner; Laura M Campbell; Vanessa Serrano; Jessica L Montoya; Elizabeth Pasipanodya; Emily W Paolillo; Donald Franklin; Ronald J Ellis; Scott L Letendre; Ann C Collier; David B Clifford; Benjamin B Gelman; Christina M Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Dilip V Jeste; Igor Grant; Robert K Heaton; David J Moore Journal: J Int Neuropsychol Soc Date: 2019-03-20 Impact factor: 2.892
Authors: Christina S Meade; Ryan P Bell; Sheri L Towe; Nan-Kuei Chen; Andrea L Hobkirk; Scott A Huettel Journal: Addict Biol Date: 2018-09-21 Impact factor: 4.280
Authors: Ryan P Bell; Sheri L Towe; Zahra Lalee; Scott A Huettel; Christina S Meade Journal: Cogn Affect Behav Neurosci Date: 2020-08 Impact factor: 3.282
Authors: Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook Journal: Subst Use Misuse Date: 2019-01-30 Impact factor: 2.164